REG - OptiBiotix Health - Partial Disposal of Shares in SkinBioTherapeutics

OptiBiotix HealthAnnouncement

01/05/2026 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260501:nRSA6718Ca&default-theme=true

RNS Number : 6718C  OptiBiotix Health PLC  01 May 2026

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

Partial Disposal of Shareholding in SkinBioTherapeutics

 

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business
developing products which reduce hunger and food cravings, enhance the gut
microbiome, and sweet fibres as healthy sugar substitutes announces that it
has disposed of 7,500,000 ordinary shares in SkinBioTherapeutics plc
(AIM:SBTX) ("SkinBioTherapeutics"), generating cash proceeds of £675,000
which will be used for the Company's general working capital purposes and are
expected to provide the Company with working capital runway into H1 2027.

 

Following the disposal, the Company's shareholding in SkinBioTherapeutics
consists of 5,700,000 ordinary shares, representing 2.2% of the total issued
share capital of SkinBioTherapeutics at the date of this announcement.

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)                     Tel: 020 7213 0880
 Liam Murray / Ludovico Lazzaretti / James Western

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has
developed a range of technologies and commercialised products which modulate
the human microbiome to help prevent and manage human disease.  Since the
Group's inception it has created a wide range of microbiome-based ingredients
and products including prebiotic products like SlimBiome®, WellBiome®,
SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc
(OPTI) business, but also skincare through its holdings in SkinBioTherapeutics
PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies
create a diverse portfolio technologies and products in an emerging area of
healthcare that is of growing interest in consumer markets throughout the
world.

Caution regarding forward looking statements

 

Certain statements in this announcement, are, or may be deemed to be,
forward-looking statements. Forward-looking statements are identified by
their use of terms and phrases such as ''believe'', ''could'', "should"
''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'',
"expect", ''will'' or the negative of those, variations or comparable
expressions, including references to assumptions.  These forward-looking
statements are not based on historical facts but rather on the Directors'
current expectations and assumptions regarding the Company's future growth,
results of operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof), competitive
advantages, business prospects and opportunities. Such forward-looking
statements reflect the Directors' current beliefs and assumptions and are
based on information currently available to the Directors.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DISBLGDSBGXDGLG



            Copyright 2019 Regulatory News Service, all rights reserved